Mirodenafil

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.

Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities. Mirodenafil administered with alcohol had a tolerability profile comparable to that of mirodenafil alone. The concurrent administration of mirodenafil with alcohol was not associated with clinically significant hemodynamic changes in these healthy male volunteers in Korea. The coadministration of ketoconazole and rifampicin resulted in significant changes in systemic exposure to mirodenafil, in these healthy Korean male volunteers.

SK3530

Angiogenesis

PDE

PDE5

——

——

862189-95-5

531.67

C26H37N5O5S

>98% (HPLC)

——

CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1

——

(-20℃)

With Ice Pack

≥ 2 years